FDA's Dapagliflozin Review To Focus On Hepatic Effects, Cancer Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will ask its Endocrinologic and Metabolic Drugs Advisory Committee to weigh these "unexpected" safety findings despite a clean cardiovascular profile for Bristol-Myers Squibb/AstraZeneca's first-in-class diabetes drug.